Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - cetirizine hydrochloride -

Indie - angličtina - Central Drugs Standard Control Organization

astria bio. - tab - 10

Filipíny - angličtina - FDA (Food And Drug Administration)

pacific healthcare phils inc - cetirizine dihydrochloride - tablet, film coated - 10mg

Indie - angličtina - Central Drugs Standard Control Organization

astria bio. - tab - 10

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cetirizine hydrochloride 10mg;   - film coated tablet - 10 mg - active: cetirizine hydrochloride 10mg   excipient: dimeticone hypromellose lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone purified talc titanium dioxide

Arménie - angličtina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

zentiva - cetirizine (cetirizine dihydrochloride) - tablets film-coated - 10mg

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

scientx australia -

Spojené státy - angličtina - NLM (National Library of Medicine)

genus lifesciences inc. - hydrocodone bitartrate (unii: no70w886kk) (hydrocodone - unii:6yks4y3wq7), homatropine methylbromide (unii: 68jrs2hc1c) (methylhomatropine - unii:p97ogj7l1l) - hycodan is indicated for the symptomatic relief of cough in adult patients 18 years of age and older. limitations of use: - not indicated for pediatric patients under 18 years of age [see use in specific populations (8.4)] . - contraindicated in pediatric patients less than 6 years of age [see contraindications (4)] . - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see warnings and precautions (5.1)], reserve hycodan for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough has been made. hycodan is contraindicated for: - all pediatric patients younger than 6 years of age [see warnings and precautions (5.2, 5.3), use in specific populations (8.4)] . - significant respiratory depression [see warnings and precautions (5.2)] . - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings and precau

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - temozolomide, quantity: 250 mg - capsule, hard - excipient ingredients: sodium lauryl sulfate; lactose; stearic acid; gelatin; titanium dioxide; sodium starch glycollate; tartaric acid; colloidal anhydrous silica; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; iron oxide black; simethicone; strong ammonia solution; potassium hydroxide - temodal capsules are indicated for the treatment of patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment; recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy. temodal capsules are also indicated as first line treatment for patients with advanced metastatic malignant melanoma.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - temozolomide, quantity: 180 mg - capsule, hard - excipient ingredients: tartaric acid; lactose; iron oxide yellow; titanium dioxide; silicon dioxide; gelatin; sodium lauryl sulfate; sodium starch glycollate; iron oxide red; stearic acid; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; simethicone - temodal capsules are indicated for the treatment of : patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment; recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy. temodal capsules are also indicated as first line treatment for patients with advanced metastatic malignant melanoma.